AR and COVID-19: Whilst there may be other contributing factors that could influence this finding (such as increased shielding of these patients), the evidence from these different conditions/diseases plus the reported gender disparities support the potential benefit of reducing androgen action – indeed of targeting the AR – in COVID-19 patients.